Skip to main content

Neurovascular Diseases

25
Publications
80.00
%Q1
71
Number of citations
68.75
% Open Access Publications
24
Ongoing Projects
1
Number of Presented Theses
5
Number of Active Clinical Trials
At the Neurovascular Research Laboratory, we have developed research projects and industry collaborations on stroke, vascular dementia, and Alzheimer’s disease by expanding our patient cohorts and conducting preclinical studies. Specifically, our work has aimed to identify biomarkers of cerebral amyloid angiopathy and post-stroke recovery, as well as to evaluate therapeutic strategies for mitigating hemorrhagic complications associated with vascular beta-amyloid deposition and infarct progression or blood-brain barrier leakage following cerebral ischemia, in preclinical models. Studies related to our research on air pollution have also been completed, demonstrating the impact of air pollutants on predicting the presence and accumulation of covert cerebrovascular disease, as well as changes in blood thrombogenicity in ischemic stroke. We have also stablished valuable collaborations with leading research groups and pharmaceutical companies in testing diagnostic and therapeutic approaches

eCORE

  • Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation
  • Brain & Mind and Behaviour
  • Chronic, Prevalent Diseases & Aging

Team

Group Leader
Anna Rosell Novel

Principal Investigator (PI)
Mar Hernández, Pilar Delgado, Olga Maisterra, Joan Montaner

Researchers
Anna Bonaterra, Toni Palasí, Alejandro Ballvé

PhD Students
Paula Garcia, Berta Páez, Marta Klimczak, Daisy Guamán

Lab Technicians
Anna Penalba, Miguel García, Júlia Valor, Kerrie Adrián, Laia Fernández, Itsasne de la Torre

Nursing and Technical Staff
Jesús Pizarro, Marcel Lamana, Belén Gutiérrez, Diana Liébana, Eva Ruiz

Selected Publications

Arrue M, Penalba A, Rodriguez-Bodero A, Elicegui A, de Homdedeu M, Cruz MJ, Simats A, Rodriguez S, Buxo X, Garcia-Rodriguez N, Pizarro J, Turner MC, Delgado P, Rosell A.
Diesel exhaust particles exposure exacerbates pro-thrombogenic plasma features ex-vivo after cerebral ischemia and accelerates tPA-induced clot-lysis in hypertensive subjects.
J Cereb Blood Flow Metab. 2024 May;44(5):772-786.
DOI: 10.1177/0271678X231214826
IF: 4.9

Li W, Shi J, Yu Z, Garcia-Gabilondo M, Held A, Huang L, Deng W, Ning M, Ji X, Rosell A, Wainger BJ, Lo EH.
SLC22A17 as a Cell Death-Linked Regulator of Tight Junctions in Cerebral Ischemia.
Stroke. 2024 Jun;55(6):1650-1659.
DOI: 10.1161/STROKEAHA.124.046736
IF: 7.9

Bonaterra-Pastra A, Sole M, Lope-Piedrafita S, Lucas-Parra M, Castellote L, Marazuela P, Pancorbo O, Rodriguez-Luna D, Hernandez-Guillamon.
The presence of circulating human apolipoprotein J reduces the occurrence of cerebral microbleeds in a transgenic mouse model with cerebral amyloid angiopathy.
Alzheimers Research & Therapy. 2024 Jul 29;16(1):169.
DOI: 10.1186/s13195-024-01541-5
IF: 8.0

Ballve A, Pizarro J, Maisterra O, Riba-Llena I, Pujadas F, Jimenez-Balado J, Palasi A, Cirach M, Turner MC, Sunyer J, Delgado P.
Ambient air pollution, covert cerebrovascular disease and cognition: results from the ISSYS study.
Eur J Neurol. 2024 Oct;31(10):e16404
DOI: 10.1111/ene.16404
IF: 4.5

Medina-Dols A, Canellas G, Capo T, Sole M, Mola-Caminal M, Cullell N, Jaume M, Nadal-Salas L, Llinas J, Gomez L, Tur S, Jimenez C, Diaz RM, Carrera C, Muino E, Gallego-Fabrega C, Soriano-Tarraga C, Ruiz-Guerra L, Pol-Fuster J, Asensio V, Muncunill J, Fleischer A, Iglesias A, Giralt-Steinhauer E, Lazcano U, Fernandez-Perez I, Jimenez-Balado J, Gabriel-Salazar M, Garcia-Gabilondo M, Lei T, Torres-Aguila NP, Carcel-Marquez J, Llado J, Olmos G, Rosell A, Montaner J, Planas AM, Rabionet R, Hernandez-Guillamon , Jimenez-Conde J, Fernandez-Cadenas I, Vives-Bauza.
Role of PATJ in stroke prognosis by modulating endothelial to mesenchymal transition through the Hippo/Notch/PI3K axis.
Cell Death Discov. 2024 Feb 17;10(1):85.
DOI: 10.1038/s41420-024-01857-z
IF: 6.1

Selected Projects

RICORS-ICTUS-Enfermedades Vasculares
Principal Investigator: Anna Rosell
Agency: Fondo de Investigación Sanitaria – ISCIII (Redes Temáticas RICORS-RD21/0006/0007)
Funding: 250,220 €
Period: 2022-2024

ELAPSE-ND: European-Latin American and Caribbean collaborative project on personalized medicine for neurological disorders.
Principal Investigator: Mar Hernandez
Agency: Fondo de Investigación Sanitaria – ISCIII-4th EU-LAC Joint Call (AC22/00051).
Funding: 174,850 €
Period: 2023-2025

Testing the endovascular route for improved neuroprotection and neurorepair in stroke recovery.
Principal Investigator: Anna Rosell
Agency: Fondo de Investigación Sanitaria – ISCIII (Proyectos de Investigación en Salud-PI22/01055)
Funding: 141,570 €
Period: 2023-2025

Role of MFGE8 as potential biomarker and therapeutic target in cerebral amyloid angiopathy. F
Principal Investigator: Mar Hernández
Agency: Fondo de Investigación Sanitaria – ISCIII (proyectos de Investigación en Salud-PI23/00082)
Funding: 208,750€
Period: 2024-2026

Endovascular Delivery of therapeutic nanocarriers for stroke recovery (End-Stroke).
Principal Investigator: Anna Rosell
Agency: Fundació La Marató (202333-30-31)
Funding: 173,750€
Period: 2024-2026

Selected Dissemination Activities

Escolab program
Place: VHIR
Date: 01/01/1970
Brief: Participation at the Barcelona City Council's Escolab program, with which the VHIR opens its doors to ESO, baccalaureate and training students. We hosted several visits at to our laboratory.

International Day of Women and Girls in Science
Place: VHIR
Date: 26/02/2025
Brief: International Day of Women and Girls in Science: Communication pills for schools.

Xerrades 30 anys VHIR 'Recerca bàsica més clínica en benefici del pacient: ictus'
Place: Hospital Vall d'Hebron
Date: 01/01/1970
Brief: Participation in activities celebrating the 30th anniversary of VHIR with the society: 'Basic and clinical research for the benefit of the patient: stroke”. Cycle of six talks between our researchers, patients, relatives and representatives of different representative groups of society.
MORE INFO

VHIR Annual Report 2024